Company / Revenue
Amphstar Pharmaceuticals, Inc. Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$719.9M
FY2025
5-year range
$437.8M / $732.0M
FY2021-FY2025
Trend
-1.7%
vs FY2024
Sector context
#52 of 155
Health Care
What the data says
At $720M, Amphstar Pharmaceuticals, Inc.'s revenue ranks #52 of 155 in the Health Care sector. Improved from $644M to $720M over the past 2 years.
Based on SEC 10-K filings.
$720M in FY2025 with a 5-year CAGR of +15.5%.
Improved from $644M to $720M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +13.0%
- 5-Year CAGR
- +15.5%
- 10-Year CAGR
- -
Sector benchmark
#52 of 155 in Health CareTop 34% of 155This company $719.9M Sector average $4.5B
▼
-83.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.5%, indicating consistent growth.
- In FY2025, revenue decreased 1.7% year-over-year.
- Ranks #52 out of 155 companies in the Health Care sector.
- Peak revenue was recorded in FY2024.
Company context
Key Data Points
- Strong profit margin: 21.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $719.9M | -1.7% |
| FY2024 | $732.0M | +13.6% |
| FY2023 | $644.4M | +29.1% |
| FY2022 | $499.0M | +14.0% |
| FY2021 | $437.8M | +25.1% |
| FY2020 | $349.8M | +8.5% |
| FY2019 | $322.4M | +9.4% |
| FY2018 | $294.7M | +22.7% |
| FY2017 | $240.2M | -5.9% |
| FY2016 | $255.2M | +1.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026